
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.
Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.
Clinical Pearls:






